11/20
03:46 pm
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
11/20
06:05 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
11/19
03:31 pm
acrs
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments [Yahoo! Finance]
Medium
Report
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments [Yahoo! Finance]
11/19
10:51 am
acrs
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs [Yahoo! Finance]
High
Report
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs [Yahoo! Finance]
11/19
08:29 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
11/19
07:30 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
11/19
07:30 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
11/18
03:42 pm
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $13.00 price target on the stock, up previously from $3.00.
Medium
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $13.00 price target on the stock, up previously from $3.00.
11/18
09:00 am
acrs
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets [Yahoo! Finance]
High
Report
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets [Yahoo! Finance]
11/18
08:50 am
acrs
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
High
Report
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
11/18
08:22 am
acrs
Aclaris Therapeutics Announces $80 Million Private Placement [Yahoo! Finance]
High
Report
Aclaris Therapeutics Announces $80 Million Private Placement [Yahoo! Finance]
11/18
08:22 am
acrs
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline [Yahoo! Finance]
High
Report
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline [Yahoo! Finance]
11/18
08:10 am
acrs
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
High
Report
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
11/18
08:10 am
acrs
Aclaris Therapeutics Announces $80 Million Private Placement
High
Report
Aclaris Therapeutics Announces $80 Million Private Placement
11/15
03:08 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/12
06:42 am
acrs
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts [Yahoo! Finance]
Low
Report
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts [Yahoo! Finance]
11/9
09:50 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
11/6
07:00 am
acrs
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Medium
Report
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
9/18
08:13 am
acrs
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial [Yahoo! Finance]
Medium
Report
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial [Yahoo! Finance]
9/17
11:11 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
9/17
07:00 am
acrs
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Low
Report
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
9/10
07:00 am
acrs
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Low
Report
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference